FDA Approves Ascendis Pharma's YORVIPATH for Hypoparathyroidism; Stock Rises 10% Post-Takeda

Aug 12, 2024, 11:40 AM

The U.S. Food and Drug Administration (FDA) has approved Ascendis Pharma's YORVIPATH® (Palopegteriparatide), marking it as the first and only treatment for hypoparathyroidism in adults. This approval positions YORVIPATH as the sole available treatment for this rare hormone disorder in the United States, following the discontinuation of Takeda's previous therapy. The announcement led to a 10% increase in Ascendis Pharma's stock price in premarket trading.